SurGenTech claims that OsteoFlo may deliver better patient outcomes. Image credit: SurGenTech / Businesswire.

SurGenTec has gained 510(k) clearance for OsteoFlo HydroFiber, a synthetic material for use in spinal surgery, from the US Food and Drug Administration (FDA).

For use in spinal surgery processes including the filling of interbody fusion cages – hollow cylinders used to fuse two vertebrae together in a spinal fusion procedure – disc spaces, and posterolateral fusions, OsteoFlo Hydrofiber uses SurGenTec’s Web Interlace Technology, which suspends particles within its fibres to prevent graft migration and ensure cohesiveness and flowability once a procedure is complete.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Having undergone almost a decade of research and development, with the FDA clearance, the Florida-based company’s material is recognised as a standalone solution equivalent to autografts, in which a patient’s own tissue is used, in spinal surgeries.

By removing the need for autograft harvesting, the company claims OsteoFlo may deliver better patient outcomes by minimising surgical time and the potential for painful recovery post-surgery.

OsteoFlo also provides an alternative to allografts, in which tissue is harvested from another person’s body, thereby mitigating potential risks associated with the process such as donor variability, disease transmission, and storage complications.

SurGenTec founder and CEO Travis Greenhalgh commented: “This product is set to revolutionise bone graft technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“OsteoFlo HydroFiber provides a novel, customisable solution for surgeons, tailored to both anatomy and procedure type. Physicians are familiar with the handling characteristics of fibre-based allograft products, and we are proud to introduce a synthetic option designed to accelerate healing without the risk of human allograft tissue.”

SurGenTec plans to officially launch OsteoFlo HydroFiber in early 2025.

Dr Micah Smith of Ortho NorthEast commented: “This innovative solution marks a significant advancement in the field, demonstrating performance that matches or exceeds autografts in both posterolateral gutters and interbody spaces.

“The fibre component enhances flowability and cohesion, preventing migration and ensuring the graft remains precisely where it is placed.”

According to GlobalData analysis, the global spinal surgery market is expected to grow at a CAGR of 3.1% over the next decade, reaching a valuation of around $16.1bn by 2033.

In 2024, SurGenTec received FDA clearance for the B-MAN Bone Marrow Aspirate Kit, a medical device designed to aid in the more efficient extraction of bone marrow for use in surgical procedures.